Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend

Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend

  • Separation of RxAir® business offers pure-play investment opportunity
  • Vystar shareholders on the Record Date of January 5, 2022 to qualify for dividend of RxAir NewCo shares

Worcester, MA, Aug. 05, 2021 (GLOBE NEWSWIRE) — Vystar® Corporation’s (OTCQB: VYST) Board of Directors has approved preliminary plans to spin off the RxAir® UV light air purification business as a separate publicly traded company (RxAir NewCo). Vystar is planning the spin-off to result in Vystar shareholders owning stock in both companies in an anticipated tax-free transaction.

Vystar and its partners have invested substantial resources in RxAir for R&D and manufacturing, along with establishing a distribution network to relaunch its product line in 2020. With the world’s attention focused on COVID-19 and airborne transmission of viruses, and the ability of RxAir UV light air purifiers to inactivate more than 99.9% of airborne viruses, bacteria and other pathogens, including the coronaviruses; influenza; tuberculosis; and MRSA, this is an optimal time for the spin-off. Vystar believes the spin-off will create equity value, making the total equity greater than the sum of the parts.

“By separating RxAir, we hope to create a high-performing, pure-play company where strategic and budget decisions can be based solely on the best interests of growing the company and revenues in that specific market without the distractions or business and budgetary demands of our subsidiaries in disparate industries,” stated Steve Rotman, CEO of Vystar Corporation. “We anticipate that creating the RxAir NewCo pure-play could unlock additional value for our shareholders, as well as make it more attractive to potential investors and customers as we plan for future product line expansion.”

Rational for Separation

  • RxAir would have its own investor base whose understanding and interests are aligned with RxAir’s value proposition, which could be more accretive to the values of the entities separately than the value they would have together
  • The company would have the ability to raise capital and pursue partnerships based on their specific industries
  • Each company would be able to recruit, motivate and retain top talent via equity-based compensation directly relating to their industry-specific contribution that impacts company performance.
  • Each company would be insulated from the highs and lows of the other.
  • Vystar and RxAir NewCo would both benefit from an undiluted concentration on their separate priorities

Vystar’s current plans for the spinoff include the following, some of which is subject to SEC and FINRA approval and other factors:

  • Approximately 36 million shares authorized for RxAir NewCo.
  • RxAir NewCo is expected to trade on the OTCQB.
  • Vystar shareholders on the Record Date of January 5th 2022 would qualify for dividend of RxAir NewCo shares
  • The Ex-Dividend Date is December 31, 2021. This is the last day that purchases of Vystar can be made that will settle in time to be eligible for the dividend
  • On the dividend Payment Date (proposed to be early in first quarter 2022), Vystar expects to issue a dividend of 2857 common shares of RxAir NewCo for every 100,000 shares of Vystar common stock held by each shareholder of record.
  • The Vystar Board has approved a $1,000,000, two-tranche capital raise for RxAir NewCo in advance of the spin-off. The raise will not affect Vystar or its shares.
  • The RxAir NewCo opening day price is expected to be $2.00 per share based on the second tranche of the capital raise for RxAir at $2.00 per share.
  • Current Vystar shareholders’ ownership of shares in Vystar will remain unchanged.
  • Vystar will retain 20% of the shares of RxAir NewCo anticipated valuation of approximately $14.5 million based on the expected opening price and number of authorized shares.
  • Vystar will transfer to RxAir NewCo the RxAir-related patents, tooling, inventory and other assets having a value of $6-$8 million.
  • Strategic Link Associates (SLA), Vystar’s RxAir manufacturing partner, will receive a seat on the RxAir NewCo Board of Directors
  • Vystar’s current Board of Directors and the SLA Board Member will initially serve as the interim Board of Directors for RxAir NewCo until the new Board members are named.
  • Steven Rotman will be the Chairman of the Board of RxAir NewCo.
  • Bryan Stone, MD, will be the CEO of RxAir NewCo.
  • Steve Rotman will remain the CEO of Vystar Corp.

Dr. Stone is a member of the Vystar Board of Directors and a long-term advisor to Vystar on product development for the healthcare industry. He brings to the Board an understanding of the challenges of new product development for start-up companies. He is the Chairman of Medicine Emeritus at Desert Regional Medical Center in Palm Springs, Calif., and the Medical Director at multiple DaVita Dialysis Centers. Dr. Stone, a nephrologist who treats many immune-compromised patients, became a spokesperson for RxAir after doing medical research on epidemiology, airborne pathogens, and air purification in an effort to keep his patients healthy.

SLA has been instrumental in R&D for new RxAir models, enhancements to existing models, rebuilding of the supply chain, and creating manufacturing efficiencies. Additionally, SLA has funded the design, electronics, prototype testing, tooling and the initial work needed to complete manufacturing for the production of the re-engineered RxAir3000 and a new RxAir500 model designed for smaller spaces. Vystar values this work at approximately $1 million.

“SLA is financially and strategically invested in Vystar and the future of RxAIr,” Dr. Stone, noted. “SLA’s experience in designing, testing and manufacturing medical and HVAC devices, as well as their extensive network of supply chain partners has been invaluable to enhancing manufacturing efficiency of RxAir, improving product performance and streamlining the manufacturing process. Their dedication to quality in every aspect of the existing products and in developing the new products lines is invaluable to RxAir. We wholeheartedly welcome them to RxAir NewCo’s Board of Directors in the formal role of helping set the strategic direction of the company.”

How RxAir Works

RxAir is an FDA-cleared UV-C light air purifier that has been proven in EPA certified lab tests to destroy a myriad of harmful airborne pathogens – without chemicals or any significant ongoing effort by the consumer. The RxAir UV-C light air purifier’s patented “kill chamber” forces the air to spiral in close proximity around three long UV-C tubes for an extended time, ensuring the proper 254 nm wavelength dosage for maximum microbicidal and neutralization activity.

RxAir improves air quality by:

  • destroying a myriad of airborne viruses and bacteria, including multiple coronaviruses; H1N1; MRSA; pneumonia; strep; tuberculosis; measles; and influenza;
  • inactivating molds, fungi and other pathogens;
  • neutralizing odors and volatile organic compounds (VOCs), such as those emitted from manufacturing processes, carpets, paints, cleaning supplies, coatings, solvents, chemicals, animals and cooking.

For information on how to become an RxAir/Rx3000 distributor and/or bulk pricing, contact info@Rxair.com or 508-791-9114.

Follow us on social media:

Twitter: @VystarCompany @RxAir

Facebook: @RxAir

Instagram: @rxair_air_purification

# # #

About Vystar Corporation:

Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Flooring and environmentally friendly technologies and products to improve lives, including RxAir® UV light air purification products that destroy harmful airborne viruses and pathogens, Vytex® Natural Rubber Latex (NRL), and Fluid Energy Solutions. Vytex is a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex for a stronger, more durable, yet environmentally safe, “green” and fully biodegradable product that can be used in a broad range of consumer and medical products. For more information, visit www.vystarcorp.com.

Contacts:

Media: Julie Shepherd, Accentuate PR, 847_275_3643, Julie@accentuatepr.com

Investors: Lee Howley, lhowley@vytex.com, 508_791_9114

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, company value, spin-off logistics, plans, pricing and timing, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Increased revenue from RxAir® UV light air purifiers that destroy more than 99.6% of airborne viruses and bacteria / Record revenue from Rotmans Furniture “Closing to Remodel” Sales Event / Increased gross profit by purchasing in larger quantities from fewer vendors

•Increased revenue from RxAir® UV light air purifiers that destroy more than 99.6% of airborne viruses and bacteria •Record revenue from Rotmans Furniture “Closing to Remodel” Sales Event •Increased gross profit by purchasing in larger quantities from fewer vendors

 Source: Vystar Corp.

 
Worcester, MA, May 24, 2021 (GLOBE NEWSWIRE) — Vystar® Corporation (OTCQB: VYST) reports milestone financial results for the first quarter of 2021 with record high revenue and profit for the first time in the company’s history. Revenue for the three months ended March 31, 2021 and 2020 were $12,868,119 and $5,932,238, respectively, for an increase of $6,935,881 or 117%.

“The increase in revenues was due to three factors: 1) the high impact ‘Closing to Remodel’ sale event at Rotmans Furniture that surpassed every quarter in Rotmans 50+ year history, 2) an increase in sales of RxAir® UV light air purification units which destroy a broad array of airborne viruses, bacteria and other pathogens, and 3) the PPP forgivable government loan to help re-opening,” Steve Rotman, Vystar CEO, stated. “The COVID pandemic has increased commercial and consumer demand for RxAir units as they seek solutions to reduce airborne viruses. Vystar’s revenues in the first quarter of 2020 were negatively impacted as COVID caused store traffic to decrease then shut down. We’ve emerged stronger than ever with multiple revenue streams, promising new product developments and a greatly enhanced cash balance sheet.”

The Company reported a significant increase in gross profit to $6,791,279 for the three-month period ended March 31, 2021 compared to gross profit of $2,999,624 for the three-month period ended March 31, 2020, an increase of $3,791,655 or 126%. The increase in gross profit was primarily due to a change in purchasing which started when the store reopened in May 2020 and the reduction of special offers. Merchandise is now being purchased in large quantities from fewer vendors.

The first quarter 2021 results also include the sales margins of a significant number of RxAir units. Deliveries on the backlog of orders for RxAir units restarted in December 2020 and continued in Q1 2021 coupled with current new orders. The backlog was a result of the Company taking advance orders for RxAir units while simultaneously spending the summer and fall of 2020 rebuilding its supply chain and contracting with a new manufacturer amid the pandemic-induced supply shortages and the manufacturing and shipping slowdowns worldwide.

The Company’s operating expenses were $5,820,622 and $3,850,177 for the three months ended March 31, 2021 and 2020, respectively, an increase of $1,970,445 or 51%. The increase was due in part to fees incurred under an agreement with a third-party agent to assist the Company with the high-impact “Closing to Remodel” sale at Rotmans, as well as increased advertising expenses.

Net income (loss) was $918,127 and ($1,367,377) for the three months ended March 31, 2021 and 2020, respectively, an increase of $2,285,504 or 167%. Net income in the quarter ended March 31, 2021 versus net loss in the same period in 2020 was due to increased sales and margins from Rotmans operations, increased sales of RxAir, and the PPP loan forgiveness.

The RxAir product line includes the following items that have achieved FDA clearance as Class II Medical Devices:

• RX400 ™ Filterless Air Purifier

• RX3000 ™ Commercial Air Purifier

Vystar sells RxAir residential and commercial units through multiple distributors and the Company’s website. Once distribution channels are firmly established, Vystar expects the air purification products will produce margins of up to 70%. Vystar has been contracted by numerous school districts and state education departments to supply units on a broad scale and is working on expanding its RxAir offerings including private labeling.

 

Mr. Rotman noted, “Vystar expects the RxAir unit volume to grow through the rest of 2021 as school districts, government agencies, churches, healthcare facilities, gyms and commercial entities re-open to normal levels. Many schools have indicated they are concerned about improving air quality overall, not just to reduce pandemic risk. With the ongoing emergence of COVID-19 variants and other viruses, and increasing awareness of how air quality affects general health, Vystar will continue to educate consumers about the benefits of RxAir and has robust manufacturing capabilities that can adjust production to meet demand.”

 

Vytex™ is a multi-patented latex raw material in which the allergy causing proteins are reduced to a level that falls at or below detection based on ASTM approved test methods. Vytex has been available as a raw material commercially for ten years and has a dedicated group of manufacturers who use it in end products such as electrical gloves, condoms, adhesives, etc. Ironically, most use Vytex for its many properties that make it a superior performing, more durable and stronger latex raw material rather than its protein properties.

Vystar’s Market Development and Distribution Agreement with Corrie MacColl, Ltd. (CMC Global) to expand the market for Vytex natural rubber liquid latex and the newly developed dry rubber has garnered much attention across a broad range of industries.

 

“We are excited to have Vytex in front of CMC Global’s broad audience via their well-established sales and distribution network,” Mr. Rotman stated. “As CMC Global’s Cameroon plantations and processing facilities resume production now after the annual winter shut down, Vytex will be produced there on a semi-exclusive basis, providing a reliable supply for customers.”

 

As of mid-2020, Vystar and the Indian Rubber Manufacturers Research Association’s (IRMRA) have been actively collaborating to develop viscoelastic deproteinized natural rubber (DPNR) variants having properties for expanding applications in specific new arenas such as green tires, biodegradable and other unique bioelastoplast product lines.

 

“Our Vytex R & D test partners in India are extremely enthusiastic about our new developments in the dry rubber and latex areas that are applicable for multiple industries,” stated William Doyle, former Vystar CEO and current Vytex Product Development Advisor. “We are looking forward to sharing these results with a broader audience this this summer. While the pandemic has halted much activity in India, fortunately we are able to share information virtually and continue our progress.”

For the full Q1 2021 Financials, visit www.sec.gov

For more information on our products, contact info@vytex.com or 508-791-9114, visit www.Vytex.com, www.Rxair.com, www.Rotmans.com, or www.VystarCorp.com or follow us on social media:

Twitter: @VystarCompany @RxAir

Facebook: @RxAir

Instagram: @rxair_air_purification

# # #

 

About Vystar Corporation:

Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, including RxAir® UV light air purification products, Vytex™ Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.

Contacts:
Vystar
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Lee Howley, lhowley@vytex.com 508-791-9114

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Vystar appoints Dr. Byron Novosad to Board of Directors

Vystar appoints Dr. Byron Novosad to Board of Directors

Source: Vystar Corp.

 
 Worcester, MA, Feb. 23, 2021 (GLOBE NEWSWIRE) — Vystar® Corporation (OTCQB: VYST) has named Byron Novosad, DDS, to the Vystar Board of Directors, effective immediately. He fills the seat vacated by Keith Osborn, MD, who has retired.

Steve Rotman, Vystar CEO, noted, “We are grateful to Dr. Osborn for his many years of service and his support of Vystar. He has provided excellent guidance and has been a valued sounding board for us on many areas. We wish him all the best in his retirement.”

“Dr. Novosad has supported us at critical junctures as an investor and in an advisory capacity over many years,” stated Rotman. “He will be an excellent addition to our Board, as he has an in-depth knowledge of Vystar’s businesses, our history, and vision for the future. His knowledge of the healthcare industry both as a practitioner, industry advisor and investor will be helpful for the development of our multiple health-related product lines, such as our patented RxAir® UV light air purifiers to battle airborne Coronaviruses and other diseases, patented Vytex® deproteinized latex and rubber for medical gloves and a wide range of products, and Fluid Energy Conversion applications.”

“As long-term shareholder and advisor to Vystar, and RxAir before its acquisition by Vystar, I have gone the extra mile to research the businesses,” stated Dr. Byron Novosad, DDS. “I have toured the rubber plantations and RxAir and Vytex factories, and have developed a thorough understanding of Vystar’s technologies. From that, I see tremendous potential. I am looking forward to playing a larger, more formal role in driving shareholder value by shaping the consistent execution and communication of Vystar’s vison, activities and achievements.”

Dr. Novosad has operated a private periodontal practice in the Houston, Texas area for 30 years, and has been a Clinical Assistant Professor of Periodontics at the Periodontal Graduate Clinic for the University of Texas Dental branch in Houston since 2007. He has served as Staff Dentist for Houston Community College School of Dental Hygiene, and was on the Advisory Board of Wharton County Jr. College School of Dental Hygiene for 37 years. He provided consulting services to the Harris County Public Health and Environmental Services Dept., UV Flu Technology (now RxAir) starting in 2011 to present, TracFind (an item tracking device), and Vystar Corp. Dr. Novosad earned his Doctor of Dental Surgery degree and Periodontics License from University of Texas at Houston.

For details on Vytex, contact info@vytex.com or 508-791-9114 or visit Vytex.com. Follow Vystar and Vytex news on Twitter: @VystarCompany

# # #

About Vystar Corporation:

Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, including RxAir® UV light air purification products, Vytex™ Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.

Contacts:
Vystar
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Lee Howley, lhowley@vytex.com 508-791-9114

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Vystar appoints Dr. Byron Novosad to Board of Directors

Vystar Partners with Corrie MacColl For Market Development, Manufacturing, Sales & Distribution of Vytex® Deproteinized Latex

Vystar Partners with Corrie MacColl For Market Development, Manufacturing, Sales & Distribution of Vytex® Deproteinized Latex

Source:  Vystar Corp.
 
 
  • Corrie MacColl to produce Vytex from world’s largest rubber plantation

Worcester, MA and Norfolk, VA, Feb. 03, 2021 (GLOBE NEWSWIRE) — Vystar® Corporation (OTCQB: VYST) has selected Corrie MacColl Limited, (CMC) a subsidiary of global natural rubber (NR) supply chain manager Halcyon Agri, as its exclusive global partner for all aspects of product market development and distribution of patented Vytex® deproteinized latex. The three-year agreement is effective immediately and auto renews annually for successive one year terms, unless terminated by either party.

Horst Sakreida, CEO of Corrie MacColl North America, stated, “We champion sustainability across the natural rubber industry, highlighted in the turnaround of our Cameroon plantations which we acquired four years ago. Today Corrie MacColl produces 100% traceable, third-party certified rubber, in line with our Sustainability Policy developed under the guidance of leading international NGOs. We have extensive insight into our carbon output and work with civil society in reducing this.” 

He added, “As part of CMC’s corporate strategy to drive innovation and sustainability across the natural rubber industry, we anticipate that raw liquid latex from our Cameroon plantations will in the future be processed into eco-friendly Vytex latex, which has all the advantages of latex, plus the added benefits of a healthier, purer product with improved strength, durability and flexibility. The synergies are strong and vital.”

Steve Rotman, Vystar CEO, said, “Tapping the global market development and distribution capabilities of Corrie MacColl provides us with an extensive reach that would take decades to establish on our own. As the recognized leader in the latex market segment, Corrie MacColl will be introducing Vytex to customers worldwide, which is expected to add shareholder value to Vystar without the expense of maintaining our own sales force and distribution network. Corrie MacColl are also leaders in the dry rubber marketplace, which we expect to enter with our newest, sustainable applications of Vytex for end products such as tires, bonding components, films, etc. We are looking forward to a mutually beneficial partnership.”

Agreement Highlights:

As part of the agreement, Vystar will:

  • Appoint CMC as its market development and distribution partner;
  • Provide support and technical assistance in the market development of the products; and
  • Grant CMC non-exclusive rights to use the Vytex trademark.

As part of the agreement, CMC will:

  • Appoint a producer for the entire Vytex product range;
  • Be responsible for managing and/or developing appropriate distribution networks, including the warehousing and shipping of liquid Vytex latex throughout the supply chain from rubber plantations to customer facilities;
  • Handle all marketing of Vytex branded latex products to potential natural rubber latex customers;
  • Act upon all infringement issues that become known. 
  • Pay a royalty fee quarterly to Vystar.

World’s Largest Rubber Plantation to produce Vytex

The enhanced Vytex production technology will be introduced and adapted in CMC’s Cameroon plantations. Corrie MacColl owns and operates 100,000 hectares (247,000 acres) in two locations in Cameroon. Balancing economic development with ecological preservation, the plantation is low density planted with only 30% planted with rubber. The remaining land is protected through CMC’s No Deforestation Policy and includes High Conservation Value (HCV), High Carbon Stock (HCS) and a 25,000 hectare (4 times the size of Manhattan Island) Community Forest. Through its Cameroon Outgrower Programme, CMC has targeted to provide income security to 13,000 smallholder families across 27,000 hectares by providing financing, tools and training for a multi-crop farm programme, based around the core crop of rubber.

Vytex latex is the result of removing non-rubber components and 99.85% of all the proteins to create an innovative, ultra-pure latex with a stronger molecular bond for greater durability, strength and flexibility that is virtually odor free and reduces the risk of developing or triggering contact allergies. An added bonus is that Vytex is biodegradable.

Vytex latex is available in low/no ammonia and low/no nitrosamine formulations to reduce chemical use for a safer manufacturing environment. It also requires significantly less water for dipped product production. Vytex offers cleaner and purer latices and rubbers that enable higher performance materials, such as improved ultra-thin film applications and cost-effective alternative bioelastoplastics. Vytex latex is ideal for applications such as medical devices, gloves, catheters and tubing; condoms; mattresses, toppers and pillows; cushions; balloons; adhesives; sports equipment; footwear; apparel and threads.

The Vytex deproteinization process, originally used for latex, is now being used to develop specialty solid rubber that offers strengths unique to the product line. This will offer new and potentially superior options for tires, plasticizers and binders, marine paint, bonding and stiffener applications, iodinated natural rubber conductive sheets, brominated natural rubber glossy surface finishes, thin films and sheets, elastic bands; medical grade rubber sheeting, anti-static and industrial sheeting, gaskets/O-ring/seals, footwear soles, vibration dampening pads and more.

For details on Vytex, contact info@vytex.com or 508-791-9114 or visit Vytex.com. Follow Vystar and Vytex news on Twitter: @VystarCompany

Hashtags #vystar, #vytex, #naturallatex, #disposablegloves, #latexgloves, #latexfoam, #nrl, #bioplastic

# # #

About Vystar Corporation:

Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, including RxAir® UV light air purification products, Vytex™ Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.

About Corrie MacColl:

At Corrie MacColl, we take a modern approach to fair and sustainable value creation in the origination and distribution of the vital material that is natural rubber. As a sustainable model corporate citizen, we are extensively invested in ecological conservation, economic and social development. Our rubber is grown, sourced and produced to the highest quality, matching supply and demand with as little impact as possible. We are consciously positioned to serve today’s rubber consumer through our customer centric merchandising model. Demand for made-to-measure rubber for use in diverse, premium and specialty applications is fulfilled by our entrenched position in key distribution markets and custom-made delivery programmes to customers.

Our products are delivered to over 1,000 customers in 350 cities through our second-to-none logistical assets, flanked by our dedicated technical advisory and support unit. Corrie MacColl is a member of the Halcyon Agri Group.

Contacts:
Vystar
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Lee Howley, lhowley@vytex.com 508-791-9114

Corrie MacColl
Media: Ryan Wiener +49 151 17630911 ryan@corrie-maccoll.com

 

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Vystar appoints Dr. Byron Novosad to Board of Directors

Vystar Issues Corporate Update on Strategic Initiatives and the Impact of COVID-19 on Brands

Vystar Issues Corporate Update on Strategic Initiatives and the Impact of COVID-19 on Brands

Worcester, MA, Feb. 01, 2021 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST), parent company of RxAir® UV light air purification products, Rotmans Furniture and Floor Covering, and Vytex® deproteinized rubber and latex, has managed numerous initiatives though the challenges of the COVID-19 pandemic and has emerged with a new and stronger supply chain, reliable manufacturing partners, an improved product offering and a growing market presence and distribution network. Vystar is pleased to update shareholders on recent achievements and plans that are currently underway to continue to build Vystar shareholder value and brand equity.

RxAir® – a Literal Breath of Fresh Air Amid the Pandemic
The COVID-19 pandemic has raised awareness of airborne disease transmission and consumers’ desire to reduce their risk of infection through the use of air purifiers, leading interest in Vystar’s RxAir ultraviolet-C (UV-C) light air purifiers to hit an all-time high. Vystar’s RxAir division offers two devices:

  • The RxAir 400 features high-intensity germicidal UV-C light proven to destroy more than 99.9% of airborne viruses and bacteria.
  • The hybrid RxAir Rx3000 features a HEPA filter which removes 99.97% of particles >0.3µm on first pass (including airborne viruses and bacteria that are typically carried on microscopic droplets >0.3 µm), complemented by germicidal UV-C light.

Both are FDA cleared Class II Medical Devices, and have been proven effective against airborne pathogens in tests at independent EPA-certified laboratories. The Rx3000 was originally designed for use in healthcare institutions and spaces up to 3000 sq. ft., while the RxAir 400 is for residential and business spaces up to 1000 sq. ft.

Amid the pandemic shutdown, RxAir engaged Strategic Link as its manufacturing management partner to rebuild the supply chain and produce the RxAir 400 with a new manufacturer. They went from square one to manufacturing the first units in four months — a significant feat in normal times and even more incredible during a pandemic that fractured supply chains across the globe. More than 10,000 units have been produced, and RxAir now has a manufacturing capacity of up to 600 units per day if needed. Units have been deployed to customers throughout schools, retail outlets, offices, recreation facilities, medical facilities and more.

RxAir initially airfreighted units from overseas at its own expense to expedite customer fulfillment. Shipments currently arrive via ocean freight approximately every two weeks, and customers can expect delivery of RxAir units within one to two days on orders of up to 1,000 units.

Strategic Link and its engineering team reviewed the Rx3000 with an eye toward improving current design, parts, manufacturing and performance, as well as considering concepts for future upgrades and accessories. The new units have passed performance and reliability testing, and Vystar continues to pursue additional certifications and testing. Vystar is scheduled to begin production of the Rx3000 during first quarter 2021, with delivery on bulk orders approximately 12 weeks after purchase.

In December, RxAir commenced a marketing and public relations campaign that includes online and television ads, social influencer and social media engagement, product reviews, earned media, and online and print advertising targeting specific demographics and geographic areas. Vystar is seeing an uptick in RxAir orders that can be tracked to specific campaign elements.

RxAir is continuing R&D efforts to upgrade existing products and develop additional products and accessories that meet market needs while expanding its internal business development team and U.S. and international distribution network.

Financing production of products and supply chain logistics is always a challenge for small companies, and RxAir is no exception. Thinking outside of the box, Vystar has been negotiating strategic partnerships to assist in scaling production, logistics and distribution without incurring additional debt or shareholder dilution.

“We are very proud to play a role in reducing the risk of airborne disease infection,” stated Steve Rotman, Vystar CEO. “Globally, there is heightened awareness of airborne disease transmission, access to the COVID vaccine is still months away for many demographic groups, and a large segment of the population is wary of the vaccine. We anticipate these conditions will contribute to continued brisk sales well into 2021. The new interest in air purification appears likely to persist overseas as well as domestically, so we are exploring expanding distribution to Europe, Asia, and Canada. Once the pandemic is behind us, customers can continue to reap the benefits of improved air quality and health as RxAir destroys a broad array of airborne pathogens and allergens.”

“We remain committed to our plan to spin out RxAir as a separate publicly traded company and issue dividend shares to shareholders of record on the record date to be determined,” Rotman added. “We look forward to sharing details on our progress in all of these areas in the coming days and months.”

Rotmans is Getting a Makeover
“We were fortunate that Rotmans Furniture and Floor Coverings received a $1.3 million federal PPP forgivable loan to help us through the COVID shutdown,” Rotman stated. “We used that quieter time to reimagine how to better serve our customers whose buying, working and living habits have undergone dramatic changes due to COVID. We anticipate that many changes, such as more consumers working from home and increased dependence on rapid home delivery, are here to stay, so we are changing our business model and doing a major renovation to continue to deliver the best customer experience as the new reality evolves.”

Rotmans’ renovation, scheduled to begin in March 2021, will facilitate the company’s shift to a smaller curated product offering that is expected to reduce overhead and generate increased margin. At the beginning of January, Rotmans began a massive clearance/inventory reduction sale to clear out current inventory lines and make way for the new product lines it will be offering after renovation is complete. The clearance sale has significantly increased sales to more than $6.5 million for the month of January, an increase of approximately 270% over January 2020 sales of $2.4 million.

New Vytex® Products and Partnerships Taking Shape
Following Vystar and the Indian Rubber Manufacturers Research Association’s (IRMRA) memorandum of understanding for research, innovation testing and technology transfer in midstream and downstream sectors of the rubber industry, the parties are actively collaborating to develop viscoelastic deproteinized natural rubber (DPNR) variants having properties for expanding applications in specific new arenas such as green tires, biodegradable and other unique bioelastoplast product lines that desire a new approach. Dry rubber Vytex offerings are paramount to this relationship and are in the latter stages of customer testing.

Production of Vytex disposable gloves has been delayed due to the major glove manufacturers having protracted COVID-related shutdowns. Vystar continues to actively pursue glove production as the market for disposable gloves is extraordinarily strong.

Vytex is a rubber hydrocarbon material with the non-rubber components and virtually all proteins that cause allergies removed. The result is ultra-pure latex and dry rubber with a more compact molecular network of greater durability and flexibility. Vytex is biodegradable, sustainably sourced, and virtually odor free with a reduced risk of developing or triggering contact allergies.

“Vytex offers superior characteristics over other latices, and has attracted the attention of some of the major players in the industry with interest in production, distribution and R&D,” stated William Doyle, former Vystar CEO and current Vytex Product Development Advisor. “We have been examining various options for expanding and centralizing Vytex production, distribution and market share through strategic partnerships that can penetrate the market globally without the long organic growth timeline or having to incur debt to expedite growth. We’re very excited about new partnerships in the works that we plan to announce shortly.”

Looking Forward
“Vystar’s future is brighter today than ever,” Rotman declared. “We are grateful to our team of highly skilled employees, associates and partners who are thinking strategically and performing exceptionally in the face of a wide array of challenges and opportunities. These three solid business divisions are moving forward, expanding their customer bases and revenue opportunities, and enhancing shareholder value. There are more promising R&D opportunities on the horizon for these divisions and Fluid Energy Conversion, our fourth division which is in the early stages of development.”

Follow Vystar and Vytex news on social media:
Facebook: @RxAir
Twitter: @VystarCompany

# # #

About Vystar Corporation:
Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, such as RxAir® UV light air purification products, Vytex Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.

Contacts:
Vystar
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Lee Howley, lhowley@vytex.com 508-791-9114
Distributor Opportunities: Steve Rotman, CEO, lhowley@vytex.com 508-791-9114

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Vystar appoints Dr. Byron Novosad to Board of Directors